Skip to main content
Erschienen in: European Surgery 2/2016

01.05.2016 | ICS congress 2015

Resectability of rectal cancer after neoadjuvant treatment – current status

verfasst von: M. Sabol, MD PhD, R. Donát, P. Chvalný, J. Palaj, D. Dyttert, P. Mračna, Š. Durdík

Erschienen in: European Surgery | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The purpose of the study was to compare our experience to recent trends of multimodal treatment of patients with locally advanced rectal cancer.

Patients and methods

209 patients with histologically proven adenocarcinoma of the rectum were treated for 3 years by a multimodal approach in a single center. Patients were evaluated for clinical and pathologic response. The type of surgical procedure and the number of retrieved lymph nodes and postoperative complications were recorded.

Results

Neoadjuvant Chemoradiotherapy (CRT) had a downstaging effect in more than half of our patients (50.61 %), and about one quarter of them achieved a complete pathologic response (22.22 %).

Conclusions

Preoperative CRT produced an encouraging down-staging effect with acceptable toxicity and perioperative complications.
Literatur
1.
Zurück zum Zitat Ferenschild FT, Dawson I, de Graaf EJ, de Wilt JH, Tetteroo GW. Preoperative radiotherapy has no value for patients with T2–3, N0 adenocarcinomas of the rectum. Dig Surg. 2009;26(4):291–296. doi:10.1159/000227771..CrossRefPubMed Ferenschild FT, Dawson I, de Graaf EJ, de Wilt JH, Tetteroo GW. Preoperative radiotherapy has no value for patients with T2–3, N0 adenocarcinomas of the rectum. Dig Surg. 2009;26(4):291–296. doi:10.1159/000227771..CrossRefPubMed
2.
Zurück zum Zitat Rödel C, Trojan J, Bechstein WO, Woeste G. Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated? Dig Dis. 2012;30(2):102–108. doi:10.1159/000342038.CrossRefPubMed Rödel C, Trojan J, Bechstein WO, Woeste G. Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated? Dig Dis. 2012;30(2):102–108. doi:10.1159/000342038.CrossRefPubMed
3.
Zurück zum Zitat Van Gijn, et al. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–582.CrossRefPubMed Van Gijn, et al. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–582.CrossRefPubMed
4.
Zurück zum Zitat Valentini V. Tumor regression grading in rectal cancer: is it time to move forward? J Clin Oncol. 2014;32(15):1534–1536.CrossRefPubMed Valentini V. Tumor regression grading in rectal cancer: is it time to move forward? J Clin Oncol. 2014;32(15):1534–1536.CrossRefPubMed
5.
Zurück zum Zitat Kulu Y, Ulrich A, Buchler MW. Resectable rectal cancer: Which patient does not need preoperative radiotherapy? Dig Dis. 2012;30(2):118–125.CrossRefPubMed Kulu Y, Ulrich A, Buchler MW. Resectable rectal cancer: Which patient does not need preoperative radiotherapy? Dig Dis. 2012;30(2):118–125.CrossRefPubMed
Metadaten
Titel
Resectability of rectal cancer after neoadjuvant treatment – current status
verfasst von
M. Sabol, MD PhD
R. Donát
P. Chvalný
J. Palaj
D. Dyttert
P. Mračna
Š. Durdík
Publikationsdatum
01.05.2016
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe Sonderheft 2/2016
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-016-0404-6

Weitere Artikel der Sonderheft 2/2016

European Surgery 2/2016 Zur Ausgabe